Nadler Financial Group Inc. reduced its stake in VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report) by 30.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,995 shares of the company’s stock after selling 1,340 shares during the period. Nadler Financial Group Inc. owned approximately 0.06% of VanEck Pharmaceutical ETF worth $244,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also added to or reduced their stakes in PPH. Allworth Financial LP acquired a new position in shares of VanEck Pharmaceutical ETF in the 4th quarter valued at approximately $28,000. Cary Street Partners Investment Advisory LLC acquired a new position in VanEck Pharmaceutical ETF during the third quarter valued at approximately $60,000. CoreFirst Bank & Trust bought a new stake in VanEck Pharmaceutical ETF during the third quarter worth $76,000. Assetmark Inc. acquired a new stake in shares of VanEck Pharmaceutical ETF in the 3rd quarter valued at $211,000. Finally, Blair William & Co. IL increased its stake in shares of VanEck Pharmaceutical ETF by 306.8% in the 3rd quarter. Blair William & Co. IL now owns 3,588 shares of the company’s stock valued at $287,000 after purchasing an additional 2,706 shares during the last quarter.
VanEck Pharmaceutical ETF Stock Performance
Shares of VanEck Pharmaceutical ETF stock traded up $0.26 during midday trading on Friday, hitting $86.78. 176,789 shares of the company traded hands, compared to its average volume of 126,243. The firm’s fifty day moving average price is $88.73 and its 200-day moving average price is $83.61. The stock has a market cap of $498.12 million, a price-to-earnings ratio of 20.57 and a beta of 0.72. VanEck Pharmaceutical ETF has a 12 month low of $74.05 and a 12 month high of $91.16.
VanEck Pharmaceutical ETF Dividend Announcement
About VanEck Pharmaceutical ETF
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
Featured Articles
- Five stocks we like better than VanEck Pharmaceutical ETF
- How to Use the MarketBeat Dividend Calculator
- 3 Stocks Leading the U.S. Agriculture Comeback
- Canada Bond Market Holiday: How to Invest and Trade
- How to Use Put Debit Spreads to Profit From Falling Stocks
- The How and Why of Investing in Biotech Stocks
- Alphabet Changes the Narrative with Its First-Ever Dividend
Want to see what other hedge funds are holding PPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report).
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.